Therapie der chronischen myeloischen Leukämie - Ziel ist die hämatologische und zytogenetische Remission

Both the treatment strategy and the prognosis of patients with chronic myeloid leukaemia (CML) has significantly improved since the introduction of the tyrosine kinase inhibitor imatinib. For patients in chronic phase CML, there are good science-based recommendations for the treatment with imatinib. In the case of imatinib intolerance or resistance, the novel tyrosine kinase inhibitors dasatinib or nilotinib can be administered. The individual pre-treatment has to be respected for therapy decisions in advanced phases of CML. Patients should be advised to take part in clinical studies.